Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Celldex Therapeutics, Inc.CLDX · Entity 4208 | Director · PRESIDENT & CEO | June 25, 2026 | June 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Celldex Therapeutics, Inc.
Report date June 25, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.09 · Expires 2036-06-25 | Direct | 375,000 |
Reported balance
After 2026-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-25 · Grant · Acquired 375,000 · Balance 375,000 F1: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2: 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.
F2: 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 25, 2026 Filed Jun 29, 2026 20:14 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantIncentive Stock Option (right to buy) · Derivative | 375,000 | $0.00 Strike: $34.09 | $0.00 |
DisclosureSEC source: 0001429933-26-000002 · form4-06292026_080621.xml · derivative · entry 1 Marucci Anthony S · CIK 0001429933 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 375,000 Underlying: Common Stock · 375,000 shares Expires 2036-06-25 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:13 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantIncentive Stock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $19.53 | $0.00 |
DisclosureSEC source: 0001415889-25-016227 · form4-06092025_080629.xml · derivative · entry 1 Marucci Anthony S · CIK 0001429933 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2035-06-05 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 5, 2026 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 13:01 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | PurchaseCommon Stock | 11,500 | $26.82 | $308,430.00 |
DisclosureSEC source: 0001415889-24-026489 · form4-11122024_011107.xml · nonDerivative · entry 1 Marucci Anthony S · CIK 0001429933 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,284 F1 · balance_after: Includes 1,092 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:12 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantIncentive Stock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $36.43 | $0.00 |
DisclosureSEC source: 0001415889-24-017159 · form4-06172024_080622.xml · derivative · entry 1 Marucci Anthony S · CIK 0001429933 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2034-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 13, 2025 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 20:13 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantIncentive Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $36.87 | $0.00 |
DisclosureSEC source: 0001415889-23-010039 · form4-06202023_080657.xml · derivative · entry 1 Marucci Anthony S · CIK 0001429933 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2033-06-15 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 15, 2024 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 20:06 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | Exercise / conversionIncentive Stock Option · Derivative | 45,000 | $0.00 Strike: $9.02 | $0.00 |
DisclosureSEC source: 0001415889-22-008769 · form4-08172022_010842.xml · derivative · entry 5 Marucci Anthony S · CIK 0001429933 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,665 Underlying: Common Stock · 45,000 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: This option was previously reported as covering 1,075,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the reverse stock split that occurred on February 8, 2019. F5 · derivative.exercise_date: As of June 13, 2022, the option is fully vested. F2 · balance_after: This option was previously reported as covering 1,075,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the reverse stock split that occurred on February 8, 2019. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 20:06 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | Exercise / conversionIncentive Stock Option · Derivative | 75,000 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001415889-22-008769 · form4-08172022_010842.xml · derivative · entry 4 Marucci Anthony S · CIK 0001429933 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 75,000 shares Expires 2029-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 20:06 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | SaleCommon Stock | 120,000 | $37.66 | $4,519,572.00 |
DisclosureSEC source: 0001415889-22-008769 · form4-08172022_010842.xml · nonDerivative · entry 3 Marucci Anthony S · CIK 0001429933 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,692 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.39 to $37.95 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 20:06 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | Exercise / conversionCommon Stock | 45,000 | $9.02 | $405,742.50 |
DisclosureSEC source: 0001415889-22-008769 · form4-08172022_010842.xml · nonDerivative · entry 2 Marucci Anthony S · CIK 0001429933 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,692 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: This option was previously reported as covering 1,075,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the reverse stock split that occurred on February 8, 2019. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 20:06 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | Exercise / conversionCommon Stock | 75,000 | $2.78 | $208,500.00 |
DisclosureSEC source: 0001415889-22-008769 · form4-08172022_010842.xml · nonDerivative · entry 1 Marucci Anthony S · CIK 0001429933 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,692 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 461 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 20:10 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantIncentive Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $22.48 | $0.00 |
DisclosureSEC source: 0001415889-22-006709 · form4-06172022_010652.xml · derivative · entry 1 Marucci Anthony S · CIK 0001429933 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2032-06-16 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 16, 2023 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 11:21 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | Exercise / conversionIncentive Stock Option · Derivative | 3,537 | $0.00 Strike: $42.00 | $0.00 |
DisclosureSEC source: 0001179110-21-008010 · edgar.xml · derivative · entry 2 Marucci Anthony S · CIK 0001429933 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,537 shares Expires 2021-08-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: This option was previously reported as covering 180,400 shares at an exercise price of $2.80 per share, but has been adjusted to reflect the Reverse Stock Split. The remaining 8,488 shares of common stock underlying the option expired on August 5, 2021. F3 · derivative.exercise_date: As of August 5, 2015, the option is fully vested. F2 · balance_after: This option was previously reported as covering 180,400 shares at an exercise price of $2.80 per share, but has been adjusted to reflect the Reverse Stock Split. The remaining 8,488 shares of common stock underlying the option expired on August 5, 2021. Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 11:21 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | Exercise / conversionCommon Stock | 3,537 | $42.00 | $148,554.00 |
DisclosureSEC source: 0001179110-21-008010 · edgar.xml · nonDerivative · entry 1 Marucci Anthony S · CIK 0001429933 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: This option was previously reported as covering 180,400 shares at an exercise price of $2.80 per share, but has been adjusted to reflect the Reverse Stock Split. The remaining 8,488 shares of common stock underlying the option expired on August 5, 2021. F1 · balance_after: Includes 4,256 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Option Plan. On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:26 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantIncentive Stock Option (right to buy) · Derivative | 224,000 | $0.00 Strike: $28.00 | $0.00 |
DisclosureSEC source: 0001179110-21-006903 · edgar.xml · derivative · entry 1 Marucci Anthony S · CIK 0001429933 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,000 Underlying: Common Stock · 224,000 shares Expires 2031-06-17 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 17, 2022 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 12:04 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantIncentive Stock Option (right to buy) · Derivative | 245,000 | $0.00 Strike: $10.38 | $0.00 |
DisclosureSEC source: 0001179110-20-007590 · edgar.xml · derivative · entry 1 Marucci Anthony S · CIK 0001429933 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,000 Underlying: Common Stock · 245,000 shares Expires 2030-06-18 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 09, 2020 Filed Jun 10, 2020 11:54 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | PurchaseCommon Stock, par value $0.001 per share | 15,000 | $3.06 | $45,900.00 |
DisclosureSEC source: 0001179110-20-007163 · edgar.xml · nonDerivative · entry 1 Marucci Anthony S · CIK 0001429933 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,438 F1 · balance_after: Includes 1,103 shares of Common Stock acquired under the Company's 2004 Employee Stock Purchase Plan. Read SEC document |
| June 19, 2019 Filed Jun 20, 2019 20:27 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantIncentive Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001179110-19-007972 · edgar.xml · derivative · entry 1 Marucci Anthony S · CIK 0001429933 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-06-19 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 11:38 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantIncentive Stock Option (right to buy) · Derivative | 1,075,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001179110-18-008563 · edgar.xml · derivative · entry 1 Marucci Anthony S · CIK 0001429933 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,075,000 Underlying: Common Stock · 1,075,000 shares Expires 2028-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 13:26 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantIncentive Stock Option (right to buy) · Derivative | 475,000 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001179110-17-009153 · edgar.xml · derivative · entry 1 Marucci Anthony S · CIK 0001429933 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475,000 Underlying: Common Stock · 475,000 shares Expires 2027-06-15 F1 · security: Represents option granted by Issuer pursuant to its 2008 Stock Option and Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 15, 2018 and the remainder vest quarterly (in equal amounts)over the subsequent 12 quarters. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.